Electronic Journal of General Medicine
April 27, 2021
Hisham Alshaikhli, Redhwan Ahmed Al-Naggar, Gwen Erlam
14 citations
Introduction: Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. \nObjective: The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. \nMethod: A qualitative study was conducted interviewing ten participants currently taking...
April 26, 2021
In patients with major depression, psilocybin was superior to a delayed-treatment control group with an effect size over 2 (relative effect sizes: 0.2 small, 0.5 medium, 1.0 large; antidepressants, on average, are 0.3). Who were these patients? Are they like yours?
International Clinical Psychopharmacology
April 23, 2021
Kyle T. Greenway, Nicolas Garel, Nathalie Goyette et al.
12 citations
Intravenous ketamine is an effective treatment of bipolar depression. One of its most important side-effects is a transient altered state of consciousness commonly referred to as dissociation. These states can be anxiety-provoking, distressing and even treatment-limiting, warranting research into mitigation strategies. In this article, we present two cases that demonstrate the potential of...
International Journal of Cognitive Therapy
April 20, 2021
Emilee E. Burgess, Steven Selchen, Benjamin D. Diplock et al.
Mindfulness-based interventions (MBIs) have emerged as clinically effective interventions for anxiety and depression although there are significant barriers to their access in the general population. The present study examined the effectiveness of a 5-week abbreviated mindfulness-based cognitive therapy (MBCT) intervention for a physician-referred, treatment-seeking, community sample (N = 54)...
Journal of Psychoactive Drugs
April 20, 2021
M. Earleywine, Brianna R. Altman, Joseph A. de Leo
8 citations
ABSTRACT Ketamine, a novel treatment for depression, has generated considerable interest and research. Few experiments address lay impressions of the credibility of ketamine treatment relative to another popular intervention for depression, CBT. Over 500 participants with depressive symptoms read descriptions of CBT, ketamine, and a treatment that combined the two. Descriptions included pros...
Brazilian Journal of Health Review
April 19, 2021
Giovanni Pereira Pio, Aline Moreira Vitorino, Naira Braga Aidar et al.
2 citations
Introdução: A depressão é um transtorno psiquiátrico caracterizado por episódios agudos ou recorrentes de humor deprimido e perda de interesse ou prazer, levando a prejuízos funcionais ao paciente. A psilocibina é uma droga psicodélica com propriedades alucinógenas e serotoninérgicas derivada de cogumelos do gênero Psilocybe. Estudos recentes demonstram potenciais efeitos terapêuticos dessa...
Frontiers in Pharmacology
April 15, 2021
Meiying Cui, Wanlin Dai, Jing Kong et al.
43 citations
Background: Major depressive disorder is associated with inflammation and immune processes. Depressive symptoms correlate with inflammatory markers and alterations in the immune system including cytokine levels and immune cell function. Th17 cells are a T cell subset which exerts proinflammatory effects. Th17 cell accumulation and Th17/Treg imbalances have been reported to be critical in the...
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
April 15, 2021
Dave Nichols
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a...
New England Journal of Medicine
April 14, 2021
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al.
1,372 citations
On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are...
Frontiers in Psychology
April 12, 2021
Henriette Löffler-stastka, Kathrin Bednar, Ingrid Pleschberger et al.
Depression has been widely studied by researchers from different fields, but its causes, and mechanism of action are still not clear. A difficulty emerges from the shifting from objective diagnosis or analysis to exploration of subjective feelings and experiences that influence the individuals' expression, communication and coping in facing depression. The integration of the experiential...